59 related articles for article (PubMed ID: 1893005)
1. [Acetylation polymorphism in lung cancer].
Laredo Quesada JM; Jara Sánchez C; Benítez Rodríguez J; Fernández Gundín MJ; Vargas Castrillón E; Muñoz González JJ; Llerena Ruiz A; Cobaleda Polo J; Pérez-Manga G
An Med Interna; 1991 Feb; 8(2):66-8. PubMed ID: 1893005
[TBL] [Abstract][Full Text] [Related]
2. Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.
Roots I; Drakoulis N; Ploch M; Heinemeyer G; Loddenkemper R; Minks T; Nitz M; Otte F; Koch M
Klin Wochenschr; 1988; 66 Suppl 11():87-97. PubMed ID: 2846954
[TBL] [Abstract][Full Text] [Related]
3. Acetylator phenotype in patients with lung carcinoma--a negative report.
Burgess EJ; Trafford JA
Eur J Respir Dis; 1985 Jul; 67(1):17-9. PubMed ID: 4054252
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphism of N-acetyltransferase 2 in patients with esophageal cancer.
Shibuta J; Eto T; Kataoka A; Inoue H; Ueo H; Suzuki T; Barnard GF; Mori M
Am J Gastroenterol; 2001 Dec; 96(12):3419-24. PubMed ID: 11774959
[TBL] [Abstract][Full Text] [Related]
5. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.
Grant DM; Mörike K; Eichelbaum M; Meyer UA
J Clin Invest; 1990 Mar; 85(3):968-72. PubMed ID: 2312737
[TBL] [Abstract][Full Text] [Related]
6. N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation.
Oyama T; Kawamoto T; Mizoue T; Yasumoto K; Kodama Y; Mitsudomi T
Anticancer Res; 1997; 17(1B):577-81. PubMed ID: 9066583
[TBL] [Abstract][Full Text] [Related]
7. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction.
Marcus PM; Hayes RB; Vineis P; Garcia-Closas M; Caporaso NE; Autrup H; Branch RA; Brockmöller J; Ishizaki T; Karakaya AE; Ladero JM; Mommsen S; Okkels H; Romkes M; Roots I; Rothman N
Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):461-7. PubMed ID: 10815690
[TBL] [Abstract][Full Text] [Related]
8. Polymorphic N-acetylation of sulfamethazine and benzidine by human liver: implication for cancer risk?
Peters JH; Gordon GR; Lin E; Green CE; Tyson CA
Anticancer Res; 1990; 10(1):225-9. PubMed ID: 2334132
[TBL] [Abstract][Full Text] [Related]
9. Acetylator genotype-dependent expression of arylamine N-acetyltransferase in human colon cytosol from non-cancer and colorectal cancer patients.
Kirlin WG; Ogolla F; Andrews AF; Trinidad A; Ferguson RJ; Yerokun T; Mpezo M; Hein DW
Cancer Res; 1991 Jan; 51(2):549-55. PubMed ID: 1985773
[TBL] [Abstract][Full Text] [Related]
10. [Genetic polymorphism in Gilbert-Meulengracht syndrome (GMS)].
Fengler JD; Baumgarten R; Eike E; Eike O; Siegmund W; Franke G; Zschiesche M
Z Gastroenterol; 1993 Feb; 31 Suppl 2():81-2. PubMed ID: 7483725
[TBL] [Abstract][Full Text] [Related]
11. Immunological evidence for N-acetyltransferase isozymes in the rabbit.
Reeves PT; Kinnear BF; Minchin RF; Ilett KF
Mol Pharmacol; 1991 Jan; 39(1):42-8. PubMed ID: 1987451
[TBL] [Abstract][Full Text] [Related]
12. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
Okkels H; Sigsgaard T; Wolf H; Autrup H
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
[TBL] [Abstract][Full Text] [Related]
13. N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus.
Kaufmann GR; Wenk M; Taeschner W; Peterli B; Gyr K; Meyer UA; Haefeli WE
Clin Pharmacol Ther; 1996 Jul; 60(1):62-7. PubMed ID: 8689813
[TBL] [Abstract][Full Text] [Related]
14. Acetylator polymorphism in human colorectal carcinoma.
Ladero JM; González JF; Benítez J; Vargas E; Fernández MJ; Baki W; Diaz-Rubio M
Cancer Res; 1991 Apr; 51(8):2098-100. PubMed ID: 2009528
[TBL] [Abstract][Full Text] [Related]
15. [Comparative analysis of N-acetylation polymorphism in humans as determined by phenotyping and genotyping].
Goldenkova-Pavlova IV; Bruskin SA; Abdeev RM; Markarova EV; Bigvava SG; Radkevich LA; Kozhekbaeva ZhM; Glotov AS; Gra OA; Zasedatelev AS; Nasedkina TV; Kurdanov KhA; Piruzian ES
Genetika; 2006 Aug; 42(8):1143-50. PubMed ID: 17025166
[TBL] [Abstract][Full Text] [Related]
16. Hepatic acetylator phenotype in bladder cancer patients.
Ladero JM; Kwok CK; Jara C; Fernandez L; Silmi AM; Tapia D; Uson AC
Ann Clin Res; 1985; 17(3):96-9. PubMed ID: 4051447
[TBL] [Abstract][Full Text] [Related]
17. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer.
Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J
Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680
[TBL] [Abstract][Full Text] [Related]
18. Acetylator polymorphism in Alzheimer's disease.
Ladero JM; Barquero MS; Coria F; Molina JA; Jiménez-Jiménez FJ; Benítez J
Eur J Med; 1993 May; 2(5):281-3. PubMed ID: 8252158
[TBL] [Abstract][Full Text] [Related]
19. Acetylator genotype-dependent expression of arylamine N-acetyltransferase and N-hydroxyarylamine O-acetyltransferase in Syrian inbred hamster intestine and colon. Identity with the hepatic acetylation polymorphism.
Ogolla F; Ferguson RJ; Kirlin WG; Trinidad A; Andrews AF; Mpezo M; Hein DW
Drug Metab Dispos; 1990; 18(5):680-5. PubMed ID: 1981720
[TBL] [Abstract][Full Text] [Related]
20. [Phenotypes of oxidation and acetylation in Alzheimer's disease--preliminary report].
Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Leszek J; Rudzik J; Grotthus B
Psychiatr Pol; 2007; 41(2):261-9. PubMed ID: 17598435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
